Regeneron confirmed it has stopped development of bbT369, a dual‑targeting CAR‑T therapy (CD79a/CD20) acquired through its 2024 purchase of 2seventy bio’s pipeline. The company halted the phase 1/2 study before entering phase 2 and will not pursue further development of bbT369. Regeneron characterized the decision as a strategic business choice that does not affect its broader cell therapy portfolio. bbT369 had used 2seventy’s megaTAL editing platform and showed early anti‑lymphoma activity in preclinical models; nevertheless, Regeneron concluded the asset would not progress. The move follows a challenging period for cell therapy investment and development, in which several large players have recently shelved or scaled back cell therapy programs. Regeneron stated the decision allows reallocation of resources to other cell therapy programs and pipeline priorities. The action underscores the ongoing portfolio re‑balancing across biopharma as companies reassess cell therapy risk profiles, manufacturing complexity and commercial prospects.